|
|||||
|
|
Scientific Considerations of Pharmaceutical Solid Polymorphism in Abbreviated New Drug Applications |
|
| Authors: | Yu Lawrence X. Furness M. Scott Raw Andre Outlaw Kathy P. Woodland Nashed Nashed E. Ramos Edwin Miller Stephen P. F. Adams Richard C. Fang Florence Patel Rashmikant M. Holcombe Frank O. Chiu Yuan-yuan Hussain Ajaz S. |
| Affiliation: | (1) Food and Drug Administration, Center for Drug Evaluation and Research, Office of Generic Drugs, Rockville, Maryland, 20855 |
| Abstract: | Purpose. This commentary is intended to provide a scientific perspective on pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).Methods. This report proposes recommendations for monitoring and controlling drug substance polymorphs and describes scientific considerations of pharmaceutical solid polymorphism in the determination of drug substance sameness.Results. It presents three decision trees for solid oral dosage forms or liquids containing undissolved drug substances to provide a process for evaluating when and how polymorphs of drug substances are monitored and controlled in ANDA submissions.Conclusions. It is scientifically concluded that differences in polymorphic composition of drug substances in generic drug products and reference-listed drugs are not directly relevant in the determination of drug substance sameness in ANDAs. |
| Keywords: | polymorphism polymorph Abbreviated New Drug Application (ANDA) drug substance drug product pharmaceutical solid |
| 本文献已被 PubMed SpringerLink 等数据库收录！ | |